Narrative review highlights targeted therapies to improve outcomes in metastatic hormone receptor-positive breast cancer post-inhibitor treatment.
Therapeutic development for post-CDK4/6i metastatic HR+ breast cancer is evolving rapidly. Identifying molecular drivers of resistance and matching patients to targeted therapies will be essential to optimize outcomes. Continued efforts toward biomarker-based treatment selection and rational sequencing strategies are expected to refine post-CDK4/6i management.
No takes yet. Share an insight, caveat, or question.
Güren et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: